Clinical Trial

Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy

Study acronym: INSTAB-PE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Pulmonary embolism (PE) is a potentially life-threatening condition caused by the obstruction of pulmonary arteries by thrombi. Patients with high-risk or intermediate-high-risk PE may require immediate reperfusion therapies, including percutaneous pulmonary thrombectomy. However, this procedure can be associated with significant hemodynamic and respiratory instability, potentially leading to shock, cardiac arrest, or the need for advanced support such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The mechanisms, timing, and causes of intraprocedural hemodynamic and respiratory deterioration during pulmonary thrombectomy are not well established. Factors such as catheter manipulation within the pulmonary arteries, increased pulmonary pressures, and the effects of anesthesia and mechanical ventilation may contribute to clinical instability. In addition, biomarkers such as NT-proBNP may reflect right ventricular strain and could help predict the risk of instability during the procedure. The aim of this prospective observational study is to determine the incidence, causes, and timing of hemodynamic and/or respiratory instability during percutaneous pulmonary thrombectomy in patients with high-risk or intermediate-high-risk PE. The study will also compare the occurrence of instability between different thrombectomy devices (FlowTriever® and Indigo® systems) and evaluate the prognostic role of baseline NT-proBNP levels. Secondary objectives include the assessment of in-hospital and 30-day mortality and their underlying causes. This study will include adult patients undergoing percutaneous pulmonary thrombectomy as part of routine clinical care. The results of this study may help improve risk stratification, guide procedural planning, and optimize the management of patients undergoing pulmonary thrombectomy, ultimately aiming to reduce morbidity and mortality.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-29.
Trial Details
NCT Number NCT07509541
Lead Sponsor Hospital Universitari Vall d'Hebron Research Institute
Conditions Pulmonary Embolism Acute
Enrollment 100 participants
Start Date 2026-04-10
Primary Completion 2030-04-10 (estimated)
Study Completion 2030-05-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-04